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Enterobacteriaceae cause different types of community- and hospital-acquired
infections. Moreover, the spread of multidrug-resistant Enterobacteriaceae is a public
health problem and the World Health Organization pointed them among the pathogens
in which the search of new antibiotics is critical. The objective of this study was to
analyze the in vitro activity of pentamidine alone and in combination with gentamicin,
tobramycin, amikacin, tigecycline, rifampicin, or doripenem against eight clinical
strains of carbapenemase-producing and/or colistin-resistant Enterobacteriaceae: five
carbapenemase-producing Klebsiella pneumoniae, one carbapenemase-producing
Escherichia coli, and two colistin-resistant Enterobacter cloacae. MIC and MBC were
determined following standard protocols. MIC results were interpreted for all the
antibiotics according to the EUCAST breakpoints but for rifampicin in which the French
FSM breakpoint was used. Bactericidal and synergistic activity of pentamidine alone and
in combination with antibiotics at concentrations of 1xMIC was measured by time-kill
curves. For one selected strain, K. pneumoniae OXA-48/CTX-M-15 time-kill curves were
performed also at 1/2xMIC of pentamidine. All studies were performed in triplicate.
Pentamidine MIC range was 200–800µg/mL. The 50, 12.5, 62.5, 87.5, and 62.5%
of the strains were susceptible to gentamicin, tobramycin, amikacin, tigecycline, and
doripenem, respectively. Only the two E. cloacae strains were susceptible to rifampicin.
Pentamidine alone at 1xMIC showed bactericidal activity against all strains, except for the
E. cloacae 32 strain. The bactericidal activity of pentamidine alone was also observed
in combination. The combinations of pentamidine were synergistic against E. cloacae
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32 with amikacin and tobramycin at 24 h and with tigecycline at 8 h. Pentamidine plus
rifampicin was the combination that showed synergistic activity against more strains (five
out of eight). Pentamidine plus doripenem did not show synergy against any strain.
At 1/2xMIC, pentamidine was synergistic with all the studied combinations against
the K. pneumoniae OXA-48/CTX-M-15 strain. In summary, pentamidine alone and in
combination shows in vitro activity against carbapenemase-producing and/or colistin-
resistant Enterobacteriaceae. Pentamidine appears to be a promising option to treat
infections caused by these pathogens.
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INTRODUCTION
Carbapenem-resistance in Enterobacteriaceae is a world health
problem that has made the World Health Organization (WHO)
to point it as a priority in the list of bacteria for which new
antibiotics are urgently needed (World Health Organization,
2017). Moreover, these pathogens have spread globally in the
past years, and are associated with carbapenemase production
as the most important resistance mechanism (Cantón et al.,
2012). Therapeutic options for infections caused by these kinds
of pathogens are scarce and colistin is often the only remaining
treatment option. However, the appearance of colistin-resistant
strains has risen dramatically in the last decade due to antibiotic
pressure in both human treatment and its use in agriculture
(Kempf et al., 2016; Olaitan et al., 2016). In a recently published
study (Hong et al., 2018), the in vitro activity of colistin was
analyzed against 356 clinical strains of Enterobacter spp. from
eight Korean hospitals, founding that 23.9 and 4.2% of E. cloacae
and E. aerogenes strains, respectively, were resistant to colistin.
In this context, clinical experience on the most effective
treatment for infections caused by these pathogens is still
scarce (Akova et al., 2012). Currently, the majority of clinical
studies conclude that the combined treatment with two or more
antimicrobials is the better option in terms of increase the
survival (Trecarichi and Tumbarello, 2017). Numerous studies,
both in vitro and in vivo, have tested the efficacy of antimicrobials
combinations against these kinds of pathogens (Pachón-Ibáñez
et al., 2018;Wang et al., 2018). Nevertheless, the best combination
depends on the susceptibility pattern of the strains and there is no
one combination that we could qualify as optimal.
Therefore, the increase in the rates of antimicrobial resistance,
the difficulty to find an optimal and effective treatment
for infections caused by these pathogens, and the lack of
the development of new families of antimicrobials by the
pharmaceutical industry (Spellberg and Rex, 2013), make urgent
the search for new approaches to combat the problem caused
by multi-resistant strains of Gram-negative bacilli (GNB)
and, specifically, by carbapenemase-producing and/or colistin-
resistant Enterobacteriaceae.
As a new treatment strategy, the repurposing of drugs for
the treatment of infections caused by these kinds of pathogens
seems especially interesting (Younis et al., 2015). This new
approach reduces the time, cost, and risk associated with the
development of antimicrobial molecules de novo. In addition, its
effectiveness has been demonstrated in different medical areas,
such as infectious diseases (Debnath et al., 2012). Despite of that
several drugs have been recycled for other clinical indications;
none has been used for the treatment of bacterial infections.
Pentamidine (in the form of isethionate) is an antiprotozoal
agent effective in trypanosomiasis, leishmaniasis, and some
fungal infections (Nguewa et al., 2005). To our knowledge,
pentamidine has never been used in clinic as antimicrobial
agent. Nevertheless, in a recent study Stokes et al. found
that pentamidine is able to disturb the outer membrane of
GNB, due to the interaction with membrane lipopolysaccharides
(Stokes et al., 2017). Moreover, they concluded that pentamidine
in combination with antimicrobials typically used for Gram-
positive cocci had synergistic activity in vitro against different
GNB and in a mice sepsis model by Acinetobacter baumannii.
The aim of this study was to evaluate in vitro the
activity of pentamidine alone and in combination
with different antimicrobials against clinical strains
of carbapenemase-producing and/or colistin-resistant
Enterobacteriaceae.
MATERIALS AND METHODS
Bacterial Strains
Eight clinical strains of carbapenemase-producing and/or
colistin-resistant Enterobacteriaceae were studied: (1) five strains
of carbapenemase-producing Klebsiella pneumoniae: Kp07, a
VIM-1 ST 1603 clone producer from Spain (Miró et al., 2013);
Kp21, co-producing VIM-1 and AmpC type beta-lactamase
DHA-1 ST 11 clone from Spain (Miró et al., 2013); Kp28, co-
producing OXA-48 ST11 clone and the extended spectrum beta-
lactamase (ESBL) CTX-M-15 from Spain (Oteo et al., 2015);
a Kp29, co-producing KPC-3 ST512 clone with the extended
spectrum beta-lactamases TEM-1 and SHV-11 from Spain
(López-Cerero et al., 2014); Kp1, a NDM-1 producer fromKenya;
(2) Ec271, a Escherichia coli NDM-1 producer from Australia
Docobo-Pérez et al., 2012; (3) two strains of Enterobacter spp.
from Spain, E. cloacae 32 and E. cloacae 297, both resistant
to colistin. Identification of these isolates was confirmed by a
Microflex LT-MALDI Biotyper mass spectrometer (Ruiz-Aragón
et al., 2018) (Bruker Daltonics GmbH, Bremen, Germany).
The presence of carbapenemase genes, and genes coding for
other beta-lactamases was confirmed by PCR and sequencing as
described previously.
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Drugs
All the drugs tested were used as standard laboratory powders
(Sigma-Aldrich, Madrid, Spain): pentamidine, aminoglycosides
(gentamicin, tobramycin, and amikacin), tigecycline, rifampicin,
and doripenem.
Antimicrobial Susceptibility Testing
The minimal inhibitory concentration (MIC) and minimal
bactericidal concentration (MBC) values were tested. MICs
of antibiotics were determined by broth microdilution as
recommended by the (Clinical and Laboratory Standards
Institute, 2012), using Mueller Hinton broth II (MHB) (Becton
Dickinson & Co., Sparks, MD, United States). MIC results
were interpreted according to the European Committee on
Antimicrobial Susceptibility Testing (http://www.eucast.org/
clinical_breakpoints/) breakpoints for all antibiotics (European
Committee on Antimicrobial Susceptibility Testing, 2018), but
rifampicin, for which the French Society for Microbiology
breakpoint was used (Soussy, 2012). Pentamidine has not
susceptibility breakpoints defined.
TheMIC value was the lowest concentration of antimicrobials
that completely inhibited the bacterial growth. To determine
the MBC values, 5-µL aliquots from the wells with no visible
growth were spread on agar plates. The MBC value was the
lowest concentration at which no colony formation occurred.
Heteroresistance in the studied strains was also evaluated by
reading the MIC at 24 and 48 h of incubation. Heteroresistance
was defined when a fraction of the inoculumwas able to grow two
dilutions above the MIC value previously determined (Ferreira
et al., 2015). All assays were performed in triplicates to ensure
reproducibility.
Time-Kill Curves
The concentrations used for pentamidine and the different
antimicrobials tested corresponded to the MIC value obtained
by microdilution. Moreover, with the Kp28 OXA-48/CTX-M-15
strain the assay was also performed at 1/2xMIC of pentamidine.
Experiments were carried out with a starting inoculum of 5× 105
cfu/mL and the drugs alone or in combination. Tubes were
incubated at 37◦C, with shaking, and samples were taken at 0,
2, 4, 8, and 24 h, serially diluted and plated (Pournaras et al.,
2011; Souli et al., 2011). Bactericidal activities of single drugs
or combination were defined as a decrease ≥ 3 log10 cfu/mL
from the starting inoculum, bacteriostatic effect was defined as
no change respect to the initial bacterial concentration during the
24 h. Synergy was defined as a decrease ≥ 2 log10 cfu/mL for the
drugs combination compared with the most active single agent
(Pachón-Ibáñez et al., 2018). Experiments were performed three
times on separate occasions.
In vitro Selection of Resistant Mutants
Time–kill curves were used. Strains elected strains were
incubated with drugs at concentrations 1×MIC, and Kp28 OXA-
48/CTX-M-15 also at pentamidine concentration of 1/2×MIC.
Furthermore, the possible combinations of pentamidine plus the
different studied antimicrobials were tested. Tubes with 20mL
of MHB with an inoculum of 5 × 105 cfu/mL of each one of
the strains were used. Tubes with the bacterial inoculum and
without drugs were used as growth controls. The bacterial growth
was counted at 0 and 24 h after incubation at 37◦C. Ten-fold
dilutions were made and 100 µL was plated on sheep blood agar
and incubated for 24 h at 37◦C. For the detection of resistant
mutants, theMIC of each one of the studied drugs was carried out
in triplicate for a maximum of five colonies at each time-point.
RESULTS
MIC/MBC and Heteroresistance
Individual MIC/MBC of each drug tested for the different
clinical strains are shown in Table 1. All the strains were
multidrug-resistant (MDR) (Magiorakos et al., 2012) except
Kp28 OXA-48/CTX-M-15 which was resistant to rifampicin
and fosfomycin. Heteroresistance was observed with tigecycline
for the Kp1 NDM-1 (1 mg/L) and Kp21 VIM-1/DHA-1
strains (1 mg/L) and with doripenem for E. cloacae 32 (1
mg/L). The antibiotic susceptibility profiles are included in the
Supplementary material.
TABLE 1 | MIC/MBC of the different drugs for the eight carbapenemase-producing and/or colistin-resistant Enterobacteriaceae clinical strains.
Clinical strains MIC/MBC (mg/L)
PEN GEN AMK TOB RIF TGC DOR
Kp07 VIM-1 400 4/16 1/1 4/4 32/32 0.5/1 1/2
Kp21 VIM-1/DHA-1 400 2/2 2/4 8 /16 > 256/> 256 0.25/> 4 > 4/> 4
Kp28 OXA-48 /CTX-M-15 400 0.25/0.25 1/1 0.5/0.5 16/16 1/4 0.5/0.5
Kp29 KPC-3 800 2/2 64/64 0.25/0.25 32/64 1/>8 > 4 / > 4
Kp1 NDM-1 400 >32/>32 > 128/> 128 > 32/> 32 > 256/> 256 0.25/> 4 1/2
Ec271 NDM-1 200 >32/>32 > 128/> 128 > 32/> 32 > 256/> 256 1/1 > 4/> 4
E. cloacae 32 800 8/16 2/4 4/8 8/8 0.5/> 4 0.25/> 4
E. cloacae 297 400 0.5/4 0.5/1 8/8 8/256 2/> 8 0.25/0.25
PEN, pentamidine; GEN, gentamicin; AMK, amikacin; TOB, tobramycin; TGC, tigecycline; RIF, rifampicin; DOR, doripenem; * Pentamidine breakpoints are not defined; GEN and TOB:
* Susceptible, MIC ≤ 2 mg/L and resistant MIC > 4 mg/L; AMK, Susceptible, MIC ≤ 8 mg/L and resistant MIC > 16 mg/L; TGC and DOR; Susceptible, MIC ≤ 1 mg/L and resistant
MIC > 2 mg/L and RIF: and resistant MIC > 16 mg/L.
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Time-Kill Curves
The bactericidal activity of the drugs alone is shown in Table 2.
Pentamidine alone at 1xMIC was bactericidal from 2 to 24 h
against six of the strains and from 4 to 24 h against Kp21
VIM-1/DHA-1; however, pentamidine alone was no bactericidal
against E. cloacae 32. Doripenem showed bactericidal activity
against three strains, and gentamycin, tobramycin, and amikacin
were bactericidal against two strains each. Tigecycline alone was
the only antimicrobial that showed not bactericidal effect against
any strain.
The in vitro activity of pentamidine in combination with
antimicrobials is shown in Table 3. The bactericidal activity
of pentamidine alone was also observed in combination.
The combinations of pentamidine were synergistic against
E. cloacae 32 with amikacin, tobramycin and rifampicin at 24 h.
Pentamidine plus rifampicin was the combination that showed
synergistic activity against more strains: Kp21 VIM-1/DHA-1,
Kp29 KPC-3 and E. cloacae 297 at 2 h and E. cloacae 32 at 24 h.
Pentamidine plus doripenem did not show synergy against any
strain.
The activity of pentamidine at 1/2xMIC in combination with
antimicrobials against Kp28 OXA-48/CTX-M-15 is showed
in Figure 1. Pentamidine 1/2xMIC plus antimicrobials
showed synergism at 24 h, but the combination with
TABLE 2 | Bactericidal activity of drugs alone against eight of carbapenemase-producing and/or colistin-resistant Enterobacteriaceae clinical strains.
Clinical strains PEN GEN AMK TOB RIF TGC DOR
Kp07 VIM-1 B
(2–24 h)
– B
(4–8 h)
– – – B
(4 h)
Kp21 VIM-1/DHA-1 B
(4–24 h)
B
(4–24 h)
– – – – –
Kp28 OXA-48 /CTX-M-15 B
(2–24 h)
– – – – – –
Kp29 KPC-3 B
(2–24 h)
B
(2–24 h)
B
(4–8 h)
B
(2–8 h)
– – –
Kp1 NDM-1 B
(2–24 h)
– – – – – –
Ec271 NDM-1 B
(2–24 h)
– – – – – –
E. cloacae 32 – B
(24 h)
– – – – B
(8–24 h)
E. cloacae 297 B
(4–24 h)
– – B
(8h)
– – B
(8 h)
PEN, pentamidine; GEN, gentamicin; AMK, amikacin; TOB, tobramycin; TGC, tigecycline; RIF, rifampicin; DOR, doripenem; B, Bactericidal; –: no bactericidal activity found; (): time frame
in hours of the in vitro activity found.
TABLE 3 | In vitro activity of pentamidine in combination with antimicrobials against eight of carbapenemase-producing and/or colistin-resistant Enterobacteriaceae
clinical strains.
Clinical strains PEN + GEN PEN + AMK PEN + TOB PEN + TGC PEN + RIF PEN + DOR
Kp07 VIM-1 B
(2–24 h)
B
(2–24 h)
B
(4–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
Kp21 VIM-1/DHA-1 B
(2–24 h)
B
(8–24 h)
B
(8–24 h)
B
(4–24 h)
B + S
(2–24 h) + (2 h)
B
(2–24 h)
Kp28 OXA-48/CTX-M-15 B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
Kp29 KPC-3 B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B + S
(2–24 h) + (2 h)
B
(2–24 h)
Kp1 NDM-1 B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
Ec271 NDM-1 B
(4–24 h)
B
(4–24 h)
B
(4–24 h)
B
(2–24 h)
B
(2–24 h)
B
(2–24 h)
E. cloacae 32 B
(24 h)
B + S
(8–24 h) + (24 h)
S
(24 h)
– B + S
(24 h) + (24 h)
B
(8–24 h)
E. cloacae 297 B
(4–24 h)
B
(2–24 h)
B
(4–24 h)
B
(4–24 h)
B + S
(2–24 h) + (2 h)
B
(4–24 h)
PEN, pentamidine; GEN, gentamicin; AMK, amikacin; TOB, tobramycin; TGC, tigecycline; RIF, rifampicin; DOR, doripenem; B, bactericidal; S, synergistic; –: no in vitro activity found; ():
time frame in hours of the in vitro activity found.
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FIGURE 1 | Time-kill curves for pentamidine (PEN) at 1/2xMIC in combination with antimicrobials against the clinical strain Kp28 OXA-48/CTX-M-15. CC: growth
control, filled circles; PEN (1/2xMIC), filled squares; antimicrobials (1xMIC), filled triangles, combination of PEN + antimicrobial, filled inverted triangles.
tobramycin due to the high bactericidal activity of tobramycin
at 24 h.
In vitro Selection of Resistant Mutants
The high bactericidal activity of pentamidine in combination
with antimicrobials, achieving bacterial concentrations close to
0 log cfu/mL did not allow to analyze the selection of resistant
mutants after 24 h incubation.
DISCUSSION
This study evaluates the use of pentamidine as antimicrobial
agent against clinical strains of carbapenemase-producing and/or
colistin-resistant Enterobacteriaceae, finding a strong in vitro
activity both with pentamidine alone and combined with
other antimicrobials, as aminoglycosides, tigecycline, doripenem,
and rifampicin. Additionally, pentamidine was synergistic
against selected strains in combination with some of these
antimicrobials, especially when was studied combined with
rifampicin.
Pentamidine showed a MIC rage against eight clinical
strains of carbapenemase-producing and/or colistin-resistant
Enterobacteriaceae from 200 to 800 mg/L. Due to its use as
an antiprotozoal agent (Nguewa et al., 2005), no susceptibility
breakpoints for pentamidine are defined. However, the MIC
values obtained are in accordance to those reported analyzing
the in vitro activity of pentamidine and five pentamidine analogs
against a E. coli strain, with MIC values ranging from 100 to
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> 200 mg/L (Stokes et al., 2017). Moreover, we found that
pentamidine atMIC concentration is bactericidal against seven of
the eight tested strains; furthermore, at 1/2xMIC was bactericidal
against the Kp28 OXA-48/CTX-M-15 producer strain.
Besides the robust bactericidal effect found with pentamidine
alone, more important is that its combinations with the
different antimicrobials tested potentiates the effect of these
antimicrobials alone against the clinical strains using the time-
kill assay. The in vitro activity observed with pentamidine in
combination with antibiotics suggests there is strong possibility
to repurpose it for antibacterial use against these difficult to
treat MDR GNB (Pachón-Ibáñez et al., 2018; Rodríguez-Baño
et al., 2018). These results are in accordance to the ones reported
by Stokes et al. in which they found that the combination
of pentamidine with rifampicin, novobiocin, erythromycin, or
vancomycin potentiated the antimicrobials alone against a wild-
type E. coli strain using chequerboard broth microdilution assays
(Stokes et al., 2017). It is noteworthy that synergistic activity
was observed when pentamidine was combined with amikacin,
tobramycin, tigecycline, and/or rifampicin against the colistin-
resistant E. cloacae 32, strain against which pentamidine alone
did not show bactericidal activity. We would also like to mention,
that no more synergistic effect with pentamidine in combination
was observed due to the excellent bactericidal activity found with
pentamidine alone at MIC concentration.
Pentamidine plus rifampicin was the combination that
showed synergism against more of the tested strains (five out of
eight). This excellent activity was also pointed out in the Stokes
et al. study, in which pentamidine synergized with rifampicin
against a wide phylogenetic distribution of antibiotic-resistant
strains, including naturally polymyxin-resistant Serratia species
(Stokes et al., 2017). The combination of rifampicin with other
antimicrobials has been proved to be useful, both in vitro and
in vivo, against other MDR GNB as Acinetobacter baumannii
(Pachón-Ibáñez et al., 2010), as other example of repurposing a
drug, such as rifampicin, previously used in staphylococcal and
mycobacterial infections.
In summary, these results suggest that pentamidine, alone or
in combination, may be a new alternative for the treatment of
infections caused by carbapenemase-producing and/or colistin-
resistant Enterobacteriaceae. To investigate further the possible
usefulness of pentamidine new data from pharmacokinetics and
pharmacodynamics and in vivo efficacy in experimental models
of infection, including the dosage and safety, are required.
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